Regeneron, Allele Settle Covid Cocktail Patent Infringement Suit

Regeneron Pharmaceuticals Inc. settled a lawsuit accusing its Covid-19 “antibody cocktail” of infringing a California biotechnology company’s patent.

Regeneron and Allele Biotechnology & Pharmaceuticals Inc. reached a settlement in principle, according to an order issued Monday in the US District Court for the Southern District of New York. The settlement comes two months after the court rejected Regeneron’s argument that it was shielded from liability by a legal safe harbor for using a patented invention while developing drug information for the US Food and Drug Administration.

• Allele sued Regeneron in October 2020 for the use of its mNeonGreen protein in ...